C

Celon Pharma SA
WSE:CLN

Watchlist Manager
Celon Pharma SA
WSE:CLN
Watchlist
Price: 26.6 PLN 2.31% Market Closed
Market Cap: 1.4B PLN
Have any thoughts about
Celon Pharma SA?
Write Note

Intrinsic Value

The intrinsic value of one CLN stock under the Base Case scenario is 8.66 PLN. Compared to the current market price of 26.6 PLN, Celon Pharma SA is Overvalued by 67%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CLN Intrinsic Value
8.66 PLN
Overvaluation 67%
Intrinsic Value
Price
C
Base Case Scenario

Valuation Backtest
Celon Pharma SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for CLN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about CLN?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Celon Pharma SA

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Celon Pharma SA

Provide an overview of the primary business activities
of Celon Pharma SA.

What unique competitive advantages
does Celon Pharma SA hold over its rivals?

What risks and challenges
does Celon Pharma SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Celon Pharma SA.

Provide P/S
for Celon Pharma SA.

Provide P/E
for Celon Pharma SA.

Provide P/OCF
for Celon Pharma SA.

Provide P/FCFE
for Celon Pharma SA.

Provide P/B
for Celon Pharma SA.

Provide EV/S
for Celon Pharma SA.

Provide EV/GP
for Celon Pharma SA.

Provide EV/EBITDA
for Celon Pharma SA.

Provide EV/EBIT
for Celon Pharma SA.

Provide EV/OCF
for Celon Pharma SA.

Provide EV/FCFF
for Celon Pharma SA.

Provide EV/IC
for Celon Pharma SA.

Show me price targets
for Celon Pharma SA made by professional analysts.

What are the Revenue projections
for Celon Pharma SA?

How accurate were the past Revenue estimates
for Celon Pharma SA?

What are the Net Income projections
for Celon Pharma SA?

How accurate were the past Net Income estimates
for Celon Pharma SA?

What are the EPS projections
for Celon Pharma SA?

How accurate were the past EPS estimates
for Celon Pharma SA?

What are the EBIT projections
for Celon Pharma SA?

How accurate were the past EBIT estimates
for Celon Pharma SA?

Compare the revenue forecasts
for Celon Pharma SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Celon Pharma SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Celon Pharma SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Celon Pharma SA compared to its peers.

Compare the P/E ratios
of Celon Pharma SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Celon Pharma SA with its peers.

Analyze the financial leverage
of Celon Pharma SA compared to its main competitors.

Show all profitability ratios
for Celon Pharma SA.

Provide ROE
for Celon Pharma SA.

Provide ROA
for Celon Pharma SA.

Provide ROIC
for Celon Pharma SA.

Provide ROCE
for Celon Pharma SA.

Provide Gross Margin
for Celon Pharma SA.

Provide Operating Margin
for Celon Pharma SA.

Provide Net Margin
for Celon Pharma SA.

Provide FCF Margin
for Celon Pharma SA.

Show all solvency ratios
for Celon Pharma SA.

Provide D/E Ratio
for Celon Pharma SA.

Provide D/A Ratio
for Celon Pharma SA.

Provide Interest Coverage Ratio
for Celon Pharma SA.

Provide Altman Z-Score Ratio
for Celon Pharma SA.

Provide Quick Ratio
for Celon Pharma SA.

Provide Current Ratio
for Celon Pharma SA.

Provide Cash Ratio
for Celon Pharma SA.

What is the historical Revenue growth
over the last 5 years for Celon Pharma SA?

What is the historical Net Income growth
over the last 5 years for Celon Pharma SA?

What is the current Free Cash Flow
of Celon Pharma SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Celon Pharma SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Celon Pharma SA

Current Assets 206.7m
Cash & Short-Term Investments 121.1m
Receivables 55.6m
Other Current Assets 30m
Non-Current Assets 369.6m
Long-Term Investments 14.8m
PP&E 323.8m
Intangibles 11.6m
Other Non-Current Assets 19.4m
Current Liabilities 79.3m
Accounts Payable 15.1m
Accrued Liabilities 29.8m
Other Current Liabilities 34.4m
Non-Current Liabilities 37.7m
Long-Term Debt 7.7m
Other Non-Current Liabilities 30m
Efficiency

Earnings Waterfall
Celon Pharma SA

Revenue
209.7m PLN
Cost of Revenue
-62.6m PLN
Gross Profit
147m PLN
Operating Expenses
-191.4m PLN
Operating Income
-44.4m PLN
Other Expenses
-1.1m PLN
Net Income
-45.5m PLN

Free Cash Flow Analysis
Celon Pharma SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

CLN Profitability Score
Profitability Due Diligence

Celon Pharma SA's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
Negative 1-Year Revenue Growth
31/100
Profitability
Score

Celon Pharma SA's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

CLN Solvency Score
Solvency Due Diligence

Celon Pharma SA's solvency score is 72/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Negative Net Debt
Low D/E
72/100
Solvency
Score

Celon Pharma SA's solvency score is 72/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CLN Price Targets Summary
Celon Pharma SA

Wall Street analysts forecast CLN stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CLN is 23.56 PLN with a low forecast of 12.12 PLN and a high forecast of 40.95 PLN.

Lowest
Price Target
12.12 PLN
54% Downside
Average
Price Target
23.56 PLN
11% Downside
Highest
Price Target
40.95 PLN
54% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CLN?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for CLN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Celon Pharma SA

Country

Poland

Industry

Pharmaceuticals

Market Cap

1.4B PLN

Dividend Yield

0.3%

Description

Celon Pharma SA is a pharmaceutical company, which engages in the research and manufacture of modern drugs. The firm focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The firm's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The firm is a subsidiary of Glatton sp z o o.

Contact

WOJ. MAZOWIECKIE
ul. Ogrodowa 2A, Kielpin
+48227515933
celonpharma.com

IPO

2016-12-01

Employees

523

Officers

CEO & President of Management Board
Dr. Maciej Wieczorek Ph.D.
CFO & Member of the Management Board
Bartosz Szalek

See Also

Discover More
What is the Intrinsic Value of one CLN stock?

The intrinsic value of one CLN stock under the Base Case scenario is 8.66 PLN.

Is CLN stock undervalued or overvalued?

Compared to the current market price of 26.6 PLN, Celon Pharma SA is Overvalued by 67%.

Back to Top